Does ENZALUTAMIDE Cause Salivary hypersecretion? 33 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 33 reports of Salivary hypersecretion have been filed in association with ENZALUTAMIDE (Xtandi). This represents 0.1% of all adverse event reports for ENZALUTAMIDE.
33
Reports of Salivary hypersecretion with ENZALUTAMIDE
0.1%
of all ENZALUTAMIDE reports
2
Deaths
2
Hospitalizations
How Dangerous Is Salivary hypersecretion From ENZALUTAMIDE?
Of the 33 reports, 2 (6.1%) resulted in death, 2 (6.1%) required hospitalization.
Is Salivary hypersecretion Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ENZALUTAMIDE. However, 33 reports have been filed with the FAERS database.
What Other Side Effects Does ENZALUTAMIDE Cause?
Fatigue (8,891)
Death (6,680)
Malignant neoplasm progression (4,696)
Prostatic specific antigen increased (3,731)
Asthenia (3,589)
Drug ineffective (3,468)
Hot flush (3,144)
Decreased appetite (3,069)
Nausea (2,898)
Dizziness (2,776)
What Other Drugs Cause Salivary hypersecretion?
CLOZAPINE (1,349)
ARIPIPRAZOLE (497)
RISPERIDONE (485)
OLANZAPINE (449)
QUETIAPINE (299)
CARBIDOPA\LEVODOPA (248)
HALOPERIDOL (216)
DIAZEPAM (185)
CLONAZEPAM (179)
LORAZEPAM (165)
Which ENZALUTAMIDE Alternatives Have Lower Salivary hypersecretion Risk?
ENZALUTAMIDE vs EPCORITAMAB
ENZALUTAMIDE vs EPCORITAMAB-BYSP
ENZALUTAMIDE vs EPERISONE
ENZALUTAMIDE vs EPHEDRINE
ENZALUTAMIDE vs EPINASTINE